Mankind Pharma Ltd reports FY26 revenue of ₹14,278 crore and proposes a €48 million investment for 70% of Armed Cell Therapeutics
- FY21–26 revenue CAGR was 18.1%; Q2 FY27 value growth was 15.7% versus IPM growth of 14.2%, with volume growth of 6.2% versus 5.2%.
- Belgium-based Armed Cell Therapeutics has lead CAR-T programmes in NHL and SCLC.
- Priorities include expanding chronic, specialty and consumer healthcare businesses, advancing biologics and R&D, and repaying acquisition debt by 2028, subject to stated conditions.
Original Filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9237ce94-3c69-4235-bcc9-22e335716703.pdf